LACTOLOGY FOUNDATION

Dimethylaminopropionylphenothiazine (ATC A03AC02) is a synthetic gastrointestinal antispasmodic with no established clinical use in lactating women and virtually no lactation‑specific data; in breastfeeding practice, other better‑studied antispasmodics are preferred and this molecule should generally be avoided or replaced by safer alternatives when possible.medpedia.framar+4

Overview and pharmacological class

Dimethylaminopropionylphenothiazine is classified under ATC code A03AC02, in the group of drugs for functional gastrointestinal disorders, synthetic antispasmodics, amides with tertiary amines.drugcentral+2
Chemically, it is a phenothiazine derivative (10-(α-dimethylaminopropionyl)phenothiazine) with antispasmodic activity on smooth muscle.pubchem.ncbi.nlm.nih+1
Clinically, it is indicated for the relief of gastrointestinal spasms and functional bowel disorders, similar in intent to other non‑cholinergic antispasmodics.sps+2
Standard reference information describes it as a prescription‑only synthetic spasmolytic, used for symptomatic control rather than disease‑modifying therapy.medpedia.framar+1

Mechanism of action and toxicological profile

The antispasmodic effect of dimethylaminopropionylphenothiazine is attributed to direct smooth‑muscle relaxation and possible weak anticholinergic actions, though detailed receptor pharmacology is poorly characterized compared with modern agents.wikipedia+2
Its phenothiazine nucleus raises theoretical concerns for central nervous system effects, anticholinergic toxicity and cardiotoxicity (e.g. QT prolongation) if high systemic concentrations are reached, by analogy with other phenothiazines.mayoclinic+2
General toxicological principles for antispasmodics include dose‑dependent anticholinergic adverse effects such as dry mouth, blurred vision, urinary retention and tachycardia, particularly in vulnerable patients or overdose.gpnotebook+2
Because current clinical use of dimethylaminopropionylphenothiazine is very limited, most safety extrapolations rely on its class (GI antispasmodics) rather than robust molecule‑specific toxicology studies.easpublisher+2

Maternal use during lactation

Modern lactation guidance emphasizes preferential use of GI antispasmodics with good breastfeeding safety data, such as hyoscine butylbromide, propantheline, peppermint oil, mebeverine or alverine.gpnotebook+1
Specialist reviews note that these preferred agents have minimal transfer into breast milk and limited infant exposure, making them suitable first‑line options for breastfeeding mothers with functional GI disorders.who+2
Dimethylaminopropionylphenothiazine is not mentioned in major lactation resources (LactMed, national breastfeeding medication guidelines), highlighting its marginal or obsolete status in current practice and the absence of risk categorization.ncbi.nlm.nih+2
In this context, the drug should be regarded as “not evaluated in breastfeeding” and used only when absolutely necessary, at the lowest effective dose and shortest duration, and preferably avoided in favor of better‑studied alternatives.who+2

Potential risks for the breastfed infant

For most medications, less than 1% of the maternal dose appears in breast milk, but risk depends on lipophilicity, protein binding, half‑life and the infant’s maturity and comorbidities.franciscanhealth+2
Phenothiazine derivatives can cross into milk and may cause infant sedation, poor feeding, hypotonia or, in higher exposures, extrapyramidal symptoms, so analogous toxicodynamic effects must be considered for dimethylaminopropionylphenothiazine.mayoclinic+2
Anticholinergic actions carry a theoretical risk of constipation, urinary retention and temperature dysregulation in the breastfed infant, especially if the drug accumulates due to a long half‑life or immature clearance.sps+2
Premature and newborn infants are at greatest risk from centrally acting or anticholinergic drugs in breast milk; therefore, unevaluated phenothiazine antispasmodics should be avoided in this group.easpublisher+2

Clinical recommendations in lactology and toxicology

When a lactating woman requires treatment for functional gastrointestinal spasms, current evidence‑based recommendations support using better‑studied antispasmodics with established breastfeeding compatibility and avoiding dimethylaminopropionylphenothiazine.who+2
If the drug has already been used inadvertently during breastfeeding, clinicians should assess infant exposure (maternal dose, timing relative to feeds) and monitor for signs of sedation, feeding difficulties, abnormal movements or urinary retention.franciscanhealth+2
In the absence of data, consultation of specialist resources (LactMed, e‑lactancia, national medicines information services) and case‑by‑case risk–benefit assessment with the mother are recommended.e-lactation+2
Discontinuation or switching to a safer alternative should be considered if repeated dosing is needed, particularly for very young or medically fragile infants.gpnotebook+2

Summary for web page content

Dimethylaminopropionylphenothiazine (ATC A03AC02) is a synthetic phenothiazine antispasmodic indicated for functional gastrointestinal disorders and spasm relief.drugcentral+2
No specific pharmacokinetic or safety studies in breastfeeding women or breastfed infants have been identified in major lactation databases, and its current clinical use appears very limited.ncbi.nlm.nih+2
Because safer and well‑characterized gastrointestinal antispasmodics are available for lactating patients, this molecule should generally be avoided during breastfeeding unless no alternatives exist and the expected maternal benefit clearly outweighs potential infant risks.sps+2
In toxicology‑lactology practice, individualized counselling, careful monitoring and preference for evidence‑based alternative drugs remain central when addressing functional bowel symptoms in breastfeeding mothers.mayoclinic+2